Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 52Leukemia, Myeloid, Acute 49Lymphoma, Non-Hodgkin 43Precursor Cell Lymphoblastic Leukemia-Lymphoma 39Lymphoma 37Leukemia 35Hodgkin Disease 35Myelodysplastic Syndromes 33Lymphoma, Mantle-Cell 20Leukemia, Lymphocytic, Chronic, B-Cell 20Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Burkitt Lymphoma 17Lymphoma, Follicular 12Hematologic Neoplasms 12Neoplasms, Plasma Cell 11Congenital Abnormalities 11Lymphoma, B-Cell, Marginal Zone 10Leukemia, Biphenotypic, Acute 9Breast Neoplasms 9Myeloproliferative Disorders 8Lymphoma, Large-Cell, Immunoblastic 8Anemia, Refractory, with Excess of Blasts 8Recurrence 7Leukemia, Myelomonocytic, Juvenile 7Leukemia, Myelomonocytic, Chronic 7Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Neuroblastoma 6Graft vs Host Disease 6Sarcoma 5

Interventions

Taxes 5Paclitaxel 5Carboplatin 4Immunoglobulin G 2Disulfides 2Cisplatin 2Bevacizumab 2temsirolimus 1pegfilgrastim 1nintedanib 1ixabepilone 1cediranib 1brivanib 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1Metformin 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Epothilones 1Doxorubicin 1Brachytherapy 1AZD 6244 1ALK1-Fc fusion protein, human 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Adenocarcinoma × Granulocyte Colony-Stimulating Factor × Clear all
NCT00006011 2015-05-19

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

GOG Foundation

Phase 3 Completed
659 enrolled 8 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡